Clinical Trial Update: Phase II Study of Bevacizumab, Pemetrexed and Carboplatin as First-Line Therapy in Malignant Pleural Mesothelioma [Phase 2]

View source ↗

Summary

Phase II trial evaluating bevacizumab with pemetrexed and carboplatin as first-line therapy for malignant pleural mesothelioma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Pleural Mesothelioma

Drugs mentioned

• Bevacizumab (bevacizumab)
• CARBOPLATIN (Carboplatin)
• Pemetrexed (pemetrexed)

Snippet

Sponsor: Armando Santoro, MD | Conditions: Mesothelioma | Phase 2 | Status: COMPLETED